Assenagon Asset Management S.A. Acquires Shares of 744,282 Dynavax Technologies Co. (NASDAQ:DVAX)

Assenagon Asset Management S.A. bought a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 744,282 shares of the biopharmaceutical company’s stock, valued at approximately $8,291,000. Assenagon Asset Management S.A. owned approximately 0.57% of Dynavax Technologies as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Dynavax Technologies by 1.4% during the first quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company’s stock worth $116,682,000 after buying an additional 126,458 shares in the last quarter. Kynam Capital Management LP lifted its holdings in shares of Dynavax Technologies by 180.0% during the 1st quarter. Kynam Capital Management LP now owns 4,239,780 shares of the biopharmaceutical company’s stock worth $52,616,000 after acquiring an additional 2,725,397 shares during the period. Renaissance Technologies LLC boosted its position in shares of Dynavax Technologies by 2.2% during the 2nd quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock worth $27,830,000 after acquiring an additional 53,600 shares in the last quarter. Great Point Partners LLC increased its stake in Dynavax Technologies by 87.7% in the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after acquiring an additional 1,109,080 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Dynavax Technologies during the second quarter valued at approximately $17,615,000. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Stock Performance

Shares of Dynavax Technologies stock opened at $11.39 on Tuesday. The company’s 50 day moving average price is $11.02 and its two-hundred day moving average price is $11.21. The firm has a market capitalization of $1.49 billion, a P/E ratio of 189.83 and a beta of 1.37. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.18 and a quick ratio of 13.18. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $15.15.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $73.80 million for the quarter, compared to analyst estimates of $76.92 million. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. During the same quarter in the previous year, the company posted $0.03 EPS. On average, equities analysts forecast that Dynavax Technologies Co. will post 0.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

DVAX has been the topic of a number of research analyst reports. The Goldman Sachs Group reduced their target price on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a research report on Tuesday, October 15th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, Dynavax Technologies has an average rating of “Moderate Buy” and an average price target of $23.67.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.